Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Merck
MKGAF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$183.00
-0.75
-0.41%
At Close: -
$160.10
-22.9
-12.51%
After Hours: Jul 24, 4:47 PM EDT
15 minutes delayed
Get Report
Comment
Merck (MKGAF) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Merck (OTC:MKGAF) Stock
Merck Stock (OTC: MKGAF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, June 24, 2024
CORRECTION: Merck KGaA Ticker Is "MKGAF"
Benzinga Newsdesk
'Merck KGaA: Phase III trials of xevinapant i...
Benzinga Newsdesk
Wednesday, December 06, 2023
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Vandana Singh
Tuesday, December 05, 2023
Germany's Merck KGaA Says Results From EVOLUT...
Benzinga Newsdesk
Tuesday, September 26, 2023
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
Vandana Singh
Thursday, August 03, 2023
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
Vandana Singh
Wednesday, July 26, 2023
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
Vandana Singh
Friday, June 30, 2023
Watching Abcam; Co Seeing Takeover Interest From Danaher, Agilent Technologies, Germany's Merck KGaA
Happy Mohamed
Tuesday, June 20, 2023
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
Vandana Singh
Wednesday, May 17, 2023
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Vandana Singh
Tuesday, April 18, 2023
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Vandana Singh
Wednesday, April 12, 2023
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
Vandana Singh
Monday, March 27, 2023
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Vandana Singh
Thursday, March 23, 2023
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Vandana Singh
Tuesday, January 03, 2023
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
Vandana Singh
Friday, December 23, 2022
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Vandana Singh
Thursday, September 30, 2021
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Vandana Singh
Tuesday, September 21, 2021
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Vandana Singh
Tuesday, August 24, 2021
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Vandana Singh
Tuesday, June 01, 2021
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
Vandana Singh
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Vandana Singh
Immutep Announced New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
Charles Gross
Friday, May 14, 2021
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
Vandana Singh
Monday, May 10, 2021
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
Vandana Singh
Tuesday, April 20, 2021
Palantir Deepens Relationship With Ringier To Help It Transform Into A Digital-First, Global Media Company
Shanthi Rexaline
Wednesday, April 07, 2021
Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
Vandana Singh
Thursday, March 18, 2021
Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma
Vandana Singh
Wednesday, March 17, 2021
Germany's Merck Invests In French Facility For Single Use Products
Vandana Singh
Monday, January 25, 2021
Pfizer Announced EC Approved BAVENCIO for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Charles Gross
Thursday, January 14, 2021
Philips, Merck KGaA Partner to Develop Personalized Fertility Treatment Solutions
Charles Gross
Tuesday, November 24, 2020
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Shanthi Rexaline
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Friday, January 10, 2020
Stocks That Hit 52-Week Highs On Friday
Lisa Levin
Thursday, January 09, 2020
Stocks That Hit 52-Week Highs On Thursday
Lisa Levin
Monday, June 15, 2015
EU Approves Merck Acquisition of Sigma-Aldric...
Benzinga
Wednesday, May 27, 2015
Merck Offers Concessions in Effort to Get EU ...
Benzinga
Tuesday, May 19, 2015
Merck KGAA CFO Says EU has Limited Concerns R...
Benzinga
Wednesday, August 07, 2013
Opexa Shares Rise Almost 200% on Positive Cha...
Benzinga
Monday, January 31, 2011
Teva Expands in Latin America - Analyst Blog
Benzinga
Wednesday, January 26, 2011
CHMP Stands Negative on MKGAF Drug - Analyst Blog
Benzinga
Thursday, January 06, 2011
Teva Expands Women's Health Biz - Analyst Blog
Benzinga
Wednesday, December 29, 2010
MKGAF Sells Agricultural Business - Analyst Blog
Benzinga
Monday, December 20, 2010
Sanofi Expands Oncology Pipeline - Analyst Blog
Benzinga
Monday, November 29, 2010
Merck KGaA MS Drug Faces Glitch - Analyst Blog
Benzinga
